|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 74.8 CHF | -0.66% |
|
+4.07% | +45.58% |
| 01:19pm | Cosmo Pharmaceuticals Names New CEO, Chairman | MT |
| Mar. 20 | Transcript : Cosmo Pharmaceuticals N.V. - Analyst/Investor Day |
Cosmo Pharmaceuticals N.V. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was EUR 65.07 million compared to EUR 60.95 million a year ago. Net income was EUR 21.67 million compared to net loss of EUR 7.9 million a year ago.
Basic earnings per share from continuing operations was EUR 1.287 compared to basic loss per share from continuing operations of EUR 0.546 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +45.58% | 1.32B | |
| +25.61% | 660B | |
| +22.66% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +12.77% | 219B | |
| -9.61% | 196B | |
| +6.39% | 199B | |
| -8.75% | 149B |
COSMO PHARMACEUTICALS N.V. 
